BioPorto Diagnostics — Key leadership changes announced

BioPorto Diagnostics (OMX: BIOPOR)

Last close As at 15/06/2024


0.02 (1.29%)

Market capitalisation


More on this equity

Research: Healthcare

BioPorto Diagnostics — Key leadership changes announced

BioPorto has announced the appointment of Anthony Pare and Neil Goldman as its new CEO and CFO, respectively, with effect from mid-November 2021. In addition, Thomas Magnussen, chairman of the Board of Directors, has decided to step down from his position, with vice chairman Christopher Lindop taking over. We note that both the CEO and CFO are US-domiciled and view these appointments as strategic given the company’s increasing focus on the US market as it inches closer to the completion of clinical trials and a subsequent de novo filing for its NGAL Test in paediatric patients.

Jyoti Prakash

Written by

Jyoti Prakash

Analyst, Healthcare


BioPorto Diagnostics

Key leadership changes announced

Leadership appointments

Pharma & biotech

21 October 2021



Market cap


Net cash (DKKm) at 30 June 2021


Shares in issue


Free float




Primary exchange

Nasdaq Copenhagen

Secondary exchange


Share price performance

Business description

BioPorto Diagnostics is a diagnostic company focused on the development and commercialisation of biomarker-based assays. Its portfolio includes the NGAL Test, for prediction of acute kidney injury, and an extensive antibody library. The company is currently undertaking clinical trials in paediatric patients, which are expected to conclude by the end of 2021, followed by the 501(k) de novo FDA filing. Approval in paediatric patients would be followed by studies in the adult population.


Jyoti Prakash, CFA

+91 981 880 0393

Maxim Jacobs, CFA

+1 646 653 7027

BioPorto Diagnostics is a research client of Edison Investment Research Limited

BioPorto has announced the appointment of Anthony Pare and Neil Goldman as its new CEO and CFO, respectively, with effect from mid-November 2021. In addition, Thomas Magnussen, chairman of the Board of Directors, has decided to step down from his position, with vice chairman Christopher Lindop taking over. We note that both the CEO and CFO are US-domiciled and view these appointments as strategic given the company’s increasing focus on the US market as it inches closer to the completion of clinical trials and a subsequent de novo filing for its NGAL Test in paediatric patients.

Year end

Revenue (DKKm)


































Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Both the new CEO and CFO come with strong technical and leadership backgrounds, with decades of executive experience between them. Incoming CEO Anthony Pare previously served as chief commercial officer of T2 Biosystems, an in vitro diagnostics company, and CFO Neil Goldman joins from Chembio Diagnostics, a global developer of point-of-care tests for infectious disease, having served as its CFO. Both companies are NASDAQ-listed.

The new appointments come at a critical juncture for BioPorto, as it is at a vital transition phase. The new United States-based appointments confirm the company’s increasing focus on progressing the NGAL Test to commercialisation as it approaches clinical approval, with the US being the key market.

BioPorto is approaching a key inflection point in its path to commercialisation. By the end of 2021, it expects to complete the pivotal study assessing its NGAL diagnostic test in critically ill paediatric patients at risk of moderate to severe acute kidney injury (AKI). BioPorto recently completed interim analysis of data (from six US children’s hospitals over a 12-month period) from the paediatric clinical trials and, while the data have not been made public, the company states that the results (in terms of sensitivity and specificity) were encouraging and support further enrolment and conclusion of the study. BioPorto is currently expanding patient enrolment to maximise the study’s statistical power and intends to onboard a further three partner hospitals to its existing 12 sites. Following conclusion of the clinical study, the company plans to apply for regulatory submission to the FDA for de novo 510(k) clearance in early 2022. In our experience, approvals in this category typically take three to six months, which could point to FDA approval as soon as Q2/Q322. Based on the results of the paediatric application, BioPorto will decide on the roadmap for the clinical studies and subsequent approval for the adult NGAL Test, a meaningfully larger market for the company.

General disclaimer and copyright

This report has been commissioned by BioPorto Diagnostics and prepared and issued by Edison, in consideration of a fee payable by BioPorto Diagnostics. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2021 Edison Investment Research Limited (Edison).


Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt


London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on BioPorto Diagnostics

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Industrials

MedservRegis — Reverse takeover transforms prospects

The reverse takeover by Regis Holdings in June 2021 strengthens the balance sheet and leaves MedservRegis well positioned to pursue growth opportunities around the globe in both existing and new markets. As global oil markets progressively recover from the effects of the pandemic and the related unprecedented declines in demand, MedservRegis is ideally situated to participate in many of the largest energy projects scheduled over the next five years. The recomposed management team is focused on returning the group to profitability, facilitating the resumption of dividends, as well as refinancing the company to lower debt costs.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free